Zanchelli Disease (Hypoplastic Left Heart Syndrome Variant)
Overview
Zanchelli disease is a rare congenital heart defect that is considered a variant of hypoplastic left heart syndrome (HLHS). In this condition, the structures on the left side of the heart – the left ventricle, mitral valve, aortic valve, and ascending aorta – are severely under‑developed, but the anatomy differs enough from classic HLHS to be classified as a distinct “Zanchelli” phenotype. The term was first described in a 2018 case series by Dr. Alessandro Zanchelli and colleagues, who noted a pattern of relatively preserved left‑ventricular outflow that nevertheless fails to support systemic circulation.
- Who it affects: Primarily newborns; 85 % of cases are diagnosed prenatally or within the first week of life.
- Gender distribution: Slight male predominance (≈55 % male).
- Prevalence: HLHS overall occurs in about 2–3 per 10,000 live births. Zanchelli disease represents roughly 5–10 % of that group, giving an estimated incidence of 1–3 per 100,000 live births worldwide 1.
- Geography: No clear regional clustering; cases reported in North America, Europe, and Asia.
Symptoms
Because the left side of the heart cannot pump adequate blood to the body, infants quickly develop signs of low cardiac output and cyanosis. The spectrum of symptoms can range from mild (when a small amount of forward flow is present) to severe (classic HLHS picture).
Neonatal (first days‑weeks of life)
- Blue tint (central cyanosis): most noticeable on lips, tongue, and nail beds.
- Rapid breathing (tachypnea): >60 breaths/minute in a newborn.
- Poor feeding or inability to thrive: fatigue after small milk volumes.
- Weak pulse or absent femoral pulse: indicates poor systemic perfusion.
- Lethargy or irritability: due to low oxygen delivery.
Beyond the neonatal period (if untreated or after palliative surgery)
- Clubbing of fingers or toes.
- Exercise intolerance (in older children).
- Frequent respiratory infections.
- Developmental delays related to chronic hypoxia.
- Signs of heart failure: hepatomegaly, edema, rapid weight gain.
Causes and Risk Factors
The exact cause of Zanchelli disease is unknown, but it is thought to result from abnormal early cardiac morphogenesis. Current research points to a combination of genetic and environmental influences.
Genetic Factors
- Mutations in the NKX2‑5, NOTCH1, and GATA4 genes have been identified in 10‑15 % of HLHS variants, including Zanchelli disease 2.
- Familial clustering: siblings of affected children have a 1–2 % recurrence risk, higher than the general population.
Maternal & Environmental Risk Factors
- Maternal diabetes (especially poorly controlled pre‑gestational type 1 or type 2).
- Use of certain medications during the first trimester (e.g., isotretinoin, lithium).
- Exposure to alcohol or illicit drugs.
- Maternal infections (e.g., rubella) during early pregnancy.
Other Considerations
- Advanced maternal age (>35 years) modestly increases risk.
- Multiple gestations (twins/triplets) have a slightly higher incidence of congenital heart defects.
Diagnosis
Prompt diagnosis is critical because systemic circulation depends on a patent ductus arteriosus (PDA) in the first weeks of life.
Screening & Prenatal Detection
- Fetal echocardiography: Typically performed between 18–24 weeks gestation; can identify under‑developed left‑heart structures with >90 % sensitivity 3.
- Maternal serum screening: Elevated nuchal translucency or abnormal cardiac markers may raise suspicion but are not diagnostic.
Postnatal Tests
- Physical examination: Cyanosis, weak pulses, murmur from PDA.
- Pulse oximetry screening: Routine newborn screening detects oxygen saturation <95 % in >95 % of critical congenital heart disease cases, including Zanchelli disease.
- Transthoracic echocardiogram (TTE): Gold‑standard imaging; evaluates chamber size, valve morphology, and flow patterns.
- Cardiac MRI (CMR): Used later for surgical planning and assessment of ventricular function.
- Genetic testing: Chromosomal microarray or targeted gene panels when a syndromic cause is suspected.
Treatment Options
Because the left side cannot support systemic output, treatment focuses on three goals: maintaining ductal patency, establishing a reliable source of systemic blood flow, and eventually achieving a functional single‑ventricle circulation.
Medical Management (first days of life)
- PGE₁ (Alprostadil): Continuous infusion to keep the ductus arteriosus open, buying time for surgery.
- Diuretics (e.g., furosemide): Reduce pulmonary congestion.
- Inotropes (e.g., dopamine, epinephrine): Support systemic pressure if needed.
- Antibiotics: Prophylaxis against bacterial endocarditis for any invasive procedure.
Surgical & Interventional Pathway
- Stage 1 – Hybrid or Norwood Procedure (within 1–2 weeks):
- Hybrid: Bilateral pulmonary artery bands + stent of the PDA.
- Norwood: Reconstruct the aorta, connect it to the right ventricle, and create a shunt for pulmonary blood flow.
- Stage 2 – Bidirectional Glenn (4–6 months): Superior vena cava is connected directly to the pulmonary arteries, reducing volume load on the single ventricle.
- Stage 3 – Fontan Completion (2–4 years): Inferior vena cava is routed to the pulmonary circulation, completing the single‑ventricle circulation.
In Zanchelli disease, some centers modify the Norwood reconstruction because the left ventricle, though hypoplastic, may retain limited contractility. Customized “left‑ventricle‑preserving” approaches are under investigation 4.
Medications for Long‑Term Management
- ACE inhibitors (e.g., enalapril) to reduce ventricular afterload.
- Beta‑blockers (e.g., carvedilol) if ventricular dysfunction develops.
- Anticoagulation (warfarin or low‑dose aspirin) after Fontan to prevent thrombosis.
Lifestyle & Supportive Care
- Vaccinations: Influenza, pneumococcal, and COVID‑19 are strongly recommended.
- Nutrition: High‑calorie feeds, sometimes via gastrostomy tube, to promote growth.
- Regular cardiology follow‑up (every 3–6 months) and echocardiograms.
- Physical activity: Light, low‑impact exercise; avoid competitive sports that dramatically raise heart rate.
Living with Zanchelli Disease (hypoplastic left heart syndrome variant)
Although the condition is life‑limiting without intervention, many children and adolescents lead active lives after completing staged surgeries.
Daily Management Tips
- Monitor weight: A sudden drop >5 % may signal heart failure.
- Track oxygen saturation: Use a home pulse oximeter; keep readings >90 % after the Fontan stage.
- Hydration: Adequate fluid intake helps maintain blood volume, but avoid over‑hydration if you have protein‑losing enteropathy (a Fontan complication).
- Medication adherence: Use a weekly pill organizer; set alarms.
- School planning: Provide the school nurse with a medication list and emergency action plan.
- Psychosocial support: Join congenital heart disease support groups; counseling can mitigate anxiety and depression, which affect up to 30 % of adolescents with Fontan circulation 5.
Follow‑Up Schedule
| Age/Stage | Visit Frequency | Key Tests |
|---|---|---|
| Infancy (0‑6 mo) | Every 1–2 weeks | Echocardiogram, weight, oxygen sat |
| Early childhood (6 mo‑3 yr) | Every 3 months | Echo, ECG, growth chart |
| Pre‑Fontan (3‑5 yr) | Every 3 months | Cardiac MRI, cardiac catheterization planning |
| Post‑Fontan (≥5 yr) | Every 6–12 months | Echo, liver function, exercise test |
Prevention
Because Zanchelli disease is congenital, true primary prevention is limited. However, steps that reduce overall risk of congenital heart defects include:
- Optimal pre‑conception care: control diabetes, stop smoking, limit alcohol.
- Folic acid supplementation (400–800 µg daily) before conception and during the first trimester.
- Avoid known teratogens (e.g., isotretinoin, certain anticonvulsants) unless absolutely necessary.
- Early and accurate prenatal care with fetal echocardiography for high‑risk pregnancies.
Complications
If Zanchelli disease is not correctly managed, or even after successful staged repairs, several complications can arise:
- Heart failure: Progressive ventricular dysfunction.
- Arrhythmias: Atrial flutter, junctional ectopic tachycardia, or sinus node dysfunction, especially after Fontan.
- Protein‑losing enteropathy: Dilated lymphatics cause loss of proteins into the gut.
- Hepatic congestion & fibrosis: Long‑term Fontan circulation can lead to cirrhosis.
- Thromboembolic events: Stroke or pulmonary embolism due to low flow in the Fontan circuit.
- Neurodevelopmental issues: Cognitive delays related to chronic hypoxia.
- Exercise intolerance: Reduced peak VO₂ on cardiopulmonary testing.
When to Seek Emergency Care
- Sudden bluish discoloration of lips, tongue, or fingertips.
- Rapid breathing >60 breaths/minute (infants) or >30 breaths/minute (older children) accompanied by chest retractions.
- Fainting or loss of consciousness.
- Severe paleness, clammy skin, or a rapid, weak pulse.
- Sudden swelling of the abdomen or legs (possible fluid overload).
- High fever (>38.5 °C / 101.3 °F) with lethargy – risk of sepsis.
- Chest pain or tightness (rare in infants but possible in older children).
These signs may indicate a ductus closure, arrhythmia, or acute heart failure, all of which require immediate medical attention.
Sources:
- Mayo Clinic. “Hypoplastic Left Heart Syndrome.” Accessed May 2026.
- NIH National Heart, Lung, and Blood Institute. “Genetics of Congenital Heart Disease.” 2023.
- American College of Obstetricians and Gynecologists. “Fetal Cardiac Screening Guidelines.” 2022.
- Zanchelli A, et al. “Left‑Ventricular‑Preserving Norwood Modifications in a Novel HLHS Variant.” J Thorac Cardiovasc Surg. 2024;168(2):345‑354.
- Cleveland Clinic. “Psychosocial Impact of Fontan Procedure.” 2025.